IP Library › Granted Patent US 12,295,968
Granted Patent B2
US 12,295,968 · App. 18/883,719 · Granted May 13, 2025

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

Inventors: Atul Bedi (Timonium, MD); Rajani Ravi (Ruxton, MD)
Assignee: The Johns Hopkins University
A61K31/704A61K38/179A61K39/3955A61K39/39558A61K45/06A61K47/6803C07K14/495C07K14/70532C07K14/70575C07K14/70578C07K14/70596C07K14/71C07K16/28C07K16/2812C07K16/2815C07K16/2827C07K16/2851C07K16/2863C07K16/2866C07K16/30C07K19/00A61K2039/505A61K2039/572C07K2317/33C07K2317/526C07K2317/622C07K2317/73C07K2317/76C07K2319/00C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,295,968
App. No.
18/883,719
Granted
May 13, 2025
Kind
B2
Abstract

The present invention is based on the seminal discovery that targeted immunomodulatory antibodies and fusion proteins can counter act or reverse immune tolerance of cancer cells. Cancer cells are able to escape elimination by chemotherapeutic agents or tumor-targeted antibodies via specific immunosuppressive mechanisms in the tumor microenvironment and such ability of cancer cells is recognized as immune tolerance. Such immunosuppressive mechanisms include immunosuppressive cytokines (for example, Transforming growth factor beta (TGF-β)) and regulatory T cells and/or immunosuppressive myeloid dendritic cells (DCs). By counteracting tumor-induced immune tolerance, the present invention provides effective compositions and methods for cancer treatment, optional in combination with another existing cancer treatment. The present invention provides strategies to counteract tumor-induced immune tolerance and enhance the antitumor efficacy of chemotherapy by activating and leveraging T cell-mediated adaptive antitumor immunity against resistant or disseminated cancer cells.

Claims (16)

1. An isolated molecule comprising:

(a) a targeting moiety comprising an antibody or antibody fragment thereof, comprising amino acids 1-119 of SEQ ID NO: 2 and the amino acid sequence of SEQ ID NO: 71, which specifically binds Epidermal Growth Factor Receptor (EGFR); and

(b) an immunomodulatory moiety comprising an amino acid sequence of the extracellular domain of Transforming growth factor-beta receptor II (TGF-βRII) comprising the amino acid sequence of SEQ ID NO: 87.

2. The molecule of claim 1 , wherein the targeting moiety comprises an antibody fragment selected from a Fab or scFv.

3. The molecule of claim 2 , wherein the antibody fragment comprises a light chain domain or a variable heavy chain domain.

4. The molecule of claim 3 , wherein the antibody fragment comprises a light chain domain comprising the amino acid sequence of SEQ ID NO: 71.

5. The molecule of claim 4 , further comprising a polypeptide linker comprising the amino acid sequence of SEQ ID NO: 104.

6. The molecule of claim 5 , wherein the light chain domain comprising the amino acid sequence of SEQ ID NO: 71 is fused to an N-terminus of the polypeptide linker comprising the amino acid sequence of SEQ ID NO: 104.

7. The molecule of claim 6 , wherein the immunomodulatory moiety comprising the amino acid sequence of SEQ ID NO: 87 is fused to a C-terminus of the polypeptide linker comprising the amino acid sequence of SEQ ID NO: 104.

8. The molecule of claim 3 , wherein the variable heavy chain domain comprises amino acids 1-119 of SEQ ID NO: 2.

9. An isolated molecule comprising:

(a) a targeting moiety comprising an antibody fragment which specifically binds Epidermal Growth Factor Receptor (EGFR) comprising a light chain domain comprising the amino acid sequence of SEQ ID NO: 71 and a variable heavy chain domain comprising amino acids 1-119 of SEQ ID NO: 2;

(b) an immunomodulatory moiety comprising an amino acid sequence of the extracellular domain of Transforming growth factor-beta receptor II (TGF-βRII) comprising the amino acid sequence of SEQ ID NO: 87; and

(c) a polypeptide linker comprising the amino acid sequence of SEQ ID NO: 104;

wherein the light chain domain comprising the amino acid sequence of SEQ ID NO: 71 is fused to an N-terminus of the polypeptide linker comprising the amino acid of SEQ ID NO: 104, and

wherein the immunomodulatory moiety comprising the amino acid sequence of SEQ ID NO: 87 is fused to a C-terminus of the polypeptide linker comprising the amino acid sequence of SEQ ID NO: 104.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2024
From: BEDI, ATUL; RAVI, RAJANI
To: THE JOHNS HOPKINS UNIVERSITY
Reel/Frame 068834/0203 →
Continuity (9)
Continuation 17694541 · Mar 14, 2022
Continuation 16601347 · Oct 14, 2019
Continuation 15362632 · Nov 28, 2016
Division 15231309 · Aug 8, 2016
Continuation 14645282 · Mar 11, 2015
Continuation 13582717
Provisional Application 61435671 · Jan 24, 2011
Provisional Application 61311255 · Mar 5, 2010
Related Publication 20250009772A1 · Jan 9, 2025
References Cited (68)
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 7795389B2 · Sun et al. · 2010 [cited by applicant]
US 7803378B2 · Tranchanf-Bunel · 2010 [cited by applicant]
US 7820165B2 · McKenna et al. · 2010 [cited by applicant]
US 8101720B2 · Lazar et al. · 2012 [cited by applicant]
US 8114845B2 · Langermann et al. · 2012 [cited by applicant]
US 8399618B2 · Lazar et al. · 2013 [cited by applicant]
US 8815247B2 · Govindappa et al. · 2014 [cited by applicant]
US 8993524B2 · Bedi · 2015 [cited by examiner]
US 9441044B2 · Bedi · 2016 [cited by examiner]
US 9850306B2 · Bedi · 2017 [cited by examiner]
US 11274156B2 · Bedi · 2022 [cited by examiner]
US 20050054832A1 · Lazar et al. · 2005 [cited by applicant]
US 20060135459A1 · Epstein et al. · 2006 [cited by applicant]
US 20060193849A1 · Krauss et al. · 2006 [cited by applicant]
US 20060263368A1 · Rosenblum et al. · 2006 [cited by applicant]
US 20070212337A1 · Bedi et al. · 2007 [cited by applicant]
US 20070244042A1 · Sun et al. · 2007 [cited by applicant]
US 20080075717A1 · Tranchand-Bunel · 2008 [cited by applicant]
US 20090053240A1 · Lazar et al. · 2009 [cited by applicant]
US 20090214533A1 · Clynes · 2009 [cited by applicant]
US 20090226435A1 · Sanjay · 2009 [cited by applicant]
US 20110052585A1 · Scaria et al. · 2011 [cited by applicant]
US 20130017199A1 · Langermann · 2013 [cited by applicant]
WO WO2009062399A1 · 2009 [cited by applicant]
WO WO2009152610A1 · 2009 [cited by applicant]
WO WO2010003118A1 · 2010 [cited by applicant]
Huang et al. A Yeast Platform for the Production of Single-Chain Antibody—Green Fluorescent Protein Fusions. Appl Environmental Microbiol 72(12): 7748-7759, 2006. [cited by examiner]
Schmidt et al. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors. Oncogene 18: 1711-1721, 1999. [cited by examiner]
Alignment of SEQ ID No. 10 of D3 with SEQ ID No. 87 of B1. [cited by applicant]
Alignment of SEQ ID No. 744 of D2 with SEQ ID No. 87 of B1. [cited by applicant]
Canadian Office Action dated Mar. 28, 2018, regarding CA 2,791,383. [cited by applicant]
Carter et al., “Identification and Validation of Cell Surface Antigens for Antibody Targeting in Oncology”, Endocr. Relat. Cancer, Dec. 2004, 11(4):659-687. [cited by applicant]
Coffelt et al., “Angiopoietin 2 Stimulates TIE2-Expressing Monocytes to Suppress T Cell Activation and to Promote Regulatory T Cell Expression”; The Journal of Immunology 2011, 186 (7), p. 4183-4190. [cited by applicant]
Contardi et al., Int. J. Cancer: 117, 538-550; 2005. [cited by applicant]
EP Communication dated Sep. 5, 2018, pursuant to Rule 114(2) EPC regarding EP 2542590. [cited by applicant]
EP Third Party Observation in European Application No. EP20200205164 dated Apr. 5, 2022, 10 pages. [cited by applicant]
European Search Report and Search Opinion Received for EP Application No. 17168491.3, mailed on Nov. 24, 2017, 5 pages. [cited by applicant]
Fernandez-Botran et al., “Soluble cytokine receptors in biological therapy”; Expert Opinion on Biological Therapy, 2002, vol. 2, Issue 6, p. 585-605. [cited by applicant]
Fonseca et al., “Capitalizing on the immunogenicity of Dying Tumor Cells”; Clinical Cancer Research 2008, 14 (6), p. 1603-1608. [cited by applicant]
Francisco et al, “PD-L1 Regulates the Development, Maintenance, and Function of Induced Regulatory T Cells”, J. Exp. Med., Dec. 2009, 206(13):3015-3029. [cited by applicant]
Haier et al., “Cell Surface Molecules and Their Prognostic Values in Assessing Colorectal Carcinomas”, Annal Surgery, Jan. 2000, 231(1):11-24. [cited by applicant]
IN Examination Report in Indian Application No. 201948021756 dated Jan. 24, 2022, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2011/027317, mailed on Sep. 20, 2012, 9 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2011/027317, mailed on Feb. 8, 2012, 11 pages. [cited by applicant]
Japanese Office Action issued on May 27, 2020, regarding JP 2018-140050. [cited by applicant]
JP Office Action in Japanese Application No. 2021-094042 dated Aug. 1, 2022, 6 pages (with English translation). [cited by applicant]
Jones et al., “Degree of CD25 expression in T-Cell lymphoma is dependent on tissue site: implications for targeted therapy”, Clinical Cancer Research, 2004, 10:5587-5594. [cited by applicant]
Jung et al.: “Double anti-angiogenic and anti-inflammatory protein valpha targeting VEGF-A and TNF-.alpha. in retinopathy and psoriasis”; JBC, vol. 286, No. 16, Feb. 23, 2011, pp. 14410-14418. [cited by applicant]
Koh et al.: “Double anti-angiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage”; Cancer Cell, vol. 18, Issue 2, Aug. 16, 2010, p. 171-184. Supplementary dat… [cited by applicant]
Kwiatkowska et al.: “Expression of soluble recombinant TGF-.beta. type II receptor fused with the Fc portion of human IgG1 (sT.beta. 11-Fc) in NSO cells”; Acta Biochimica Polonica, 2006, 53(2), pp. 361-369. [cited by applicant]
Letourneau et al,: “IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets”; J Allergy Clin Immunol. 2009, 123(4), pp. 758-762. [cited by applicant]
Malek et al.: “Interleukin-2 receptor signaling: at the interface between tolerance and immunity”; Immunity 2010, vol. 33, Issue 2, p. 153-165. [cited by applicant]
Office Action received for European Application No. 11751481.0, mailed on Jan. 22, 2016, 3 pages. [cited by applicant]
Podar et al.: “Inhibition of the TGF-.beta. signaling pathway in tumor cells”; Recent Results in Cancer Research, 2007, vol. 172, p. 77-97. [cited by applicant]
Regnault et al.: “Fc.gamma. Receptor-mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I-restricted Antigen Presentation after Immune Complex Internalization”; J. Exp. Med., 1999… [cited by applicant]
Rose-John et al. 2007. Expert Opinion in Therapeutic Targets. 11:613-624. [cited by applicant]
Schrama et al.: “Antibody targeted drugs as cancer therapeutics”; Nature Reviews Drug Discovery, Jan. 20, 2006, vol. 5, p. 147-159. [cited by applicant]
Supplementary European Search Report received for EP Patent Application No. 11751481.0, mailed on Jun. 27, 2013, 16 pages. [cited by applicant]
Trail et al.: “Monoclonal antibody drug conjugates in the treatment of cancer”; Current Opinion in Immunology, 1999, vol. 11, Issue 5, p. 584-588. [cited by applicant]
U.S. Appl. No. 61/311;255, Mar. 5, 2010, Atul Bedi. [cited by applicant]
U.S. Appl. No. 61/435,671, filed Jan. 24, 2011, Atul Bedi. [cited by applicant]
Wang et al.: “Tumor necrosis factor and cancer, buddies or foes?”; Acta Pharmacologica Sinica, 2008, 29 (11), p. 1275-1288. [cited by applicant]
Yang et al.: “The role of T.sub.reg in the cancer immunological response”; American Journal of Immunology, 2009, 5 (1), p. 17-28. [cited by applicant]
Yao and Chen: “Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Ce11 Dysfunction in Cancer”; D.I. Gabrilovich, A.A. Hurwitz (eds.), Tumor-Induced Immune Suppression. pp. 29-40 .COPYRGT. Springer 2008. [cited by applicant]
Zhang et al., “Design and Optimization of a Linker for Fusion Protein Construction,” Prog. Natural Sci. (2009), 19:1197-1200, Elsevier. [cited by applicant]
Zhang et al: “Expression of a Soluble TGF-.beta. Receptor by Tumor Cells Enhances Dendritic Cell/Tumor FusionVaccine Efficacy.sup.1”; J. Immunology, 2008, 181, pp. 3690-3697. [cited by applicant]